progression or unacceptable toxicity or for up to 35 cycles. The primary endpoint will be PFS. An exploratory analysis on tumor biopsies before and after NAD will be performed, to identify immunogenic and genetic markers of responsiveness or resistance to NAD treatment.

Results Trial in progress: there are no available results at the time of submission.

Conclusions Trial in progress: there are no available conclusions at the time of submission.

Objectives A 2-part, multicohort, phase 1b/2 trial, ENGOT-cx8/GOG-3024/inovatTV 205 (NCT03786081), established the recommended phase 2 dose (RP2D) and feasibility of tisotumab vedotin (TV) in combination with bevaczimab, pembrolizumab, or carboplatin (Monk et al, IGCS 2021). The current report details a new, ongoing, inovatTV 205 dose-expansion cohort evaluating combinations of TV, pembrolizumab, and carboplatin ± bevacizumab.

Methods The new cohort will include adult patients with recurrent or stage IVB squamous, adenosquamous, or adeno-carcinoma of the cervix who received no prior systemic therapy and had an ECOG PS of 0 or 1. Patients will be treated as per local protocol. The follow-up is three years.

TP004/#1457 TRIAL IN PROGRESS OF ENGOT-CX8/GOG-3024/INNOVATV 205: ADDITION OF A NEW COHORT USING FIRST-LINE TISOTUMAB VEDOTIN + PEBROLIZUMAB + CARBOPLATIN ± BEVACIZUMAB IN RECURRENT/METASTATIC CERVICAL CANCER

1Ignace Vergote, 2Mansoor Mirza, 3Jaidul Sehoul, 4Domenica Lorusso, 5Fatih Kose, 6David Cibula, 7Anneke Westermann, 8Debrahille Collins, 9Susana Banerjee, 10Ana Oakinin, 11Ibrahima Soumaoro, 12Shweta Jain, 13Bradley Monk.

Leuven Cancer Institute and BGOG (Belgium and Luxembourg Gynaecological Oncology Group), University Hospitals Leuven, Leuven, Belgium; 2Rigshospitalet, Copenhagen University Hospital, Department of Cancer Treatment, Copenhagen, Denmark; 3Charité University Hospital Campus Virchow Klinikum, Gynecology and Gynecological Oncology, Berlin, Germany; 4Fondazione Policlinico Universitario A.Gemelli IRCCS, Gynecologic Oncology, Rome, Italy; 5Baskent University, Department of Medical Oncology, Yangehir/Adana, Turkey; 6First Faculty of Medicine, Charles University and General University Hospital, Department of Obstetrics and Gynecology, Prague, Czech Republic; 7Dutch Gynecological Oncology Group (DGOG) and Amsterdam University Medical Centers, Department of Medical Oncology, Amsterdam, Netherlands; 8Cork University Hospital, Department of Medical Oncology, Cork, Ireland; 9The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Gynaecology Unit, London, UK; 10Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, and GEICO, Gynecologic Cancer Programme, Barcelona, Spain; 11Genmab US, Inc., Oncology, Plainsboro, USA; 12Seagen Inc., Late Stage Development, Bothell, USA; 13Director, Principal Investigator, Community Research Development, HonorHealth Research Institute, Division of Gynecologic Oncology, Phoenix, USA.

10.1136/ijgc-2022-igcs.513

Objectives The primary objective of the CONTESSA/NEOCON-F trial (NCT04016389) is to assess the feasibility of preserving fertility in women with FIGO 2018 stage IB2 cervical cancer by administering neo-adjuvant chemotherapy (NACT) followed by fertility sparing surgery (FSS).

Methods This ongoing multi-center, phase II clinical trial will accrue 90 premenopausal women, aged between 18 and 40 years, who are diagnosed with lymph-node negative, FIGO 2018 stage IB2 cervical cancer and who have a desire to preserve fertility. Patients will receive three cycles paclitaxel and platinum-based chemotherapy. Following NACT the response will be evaluated by clinical examination and MRI. Patients with complete or partial response (residual lesion <2 cm) will be eligible for FSS: a conization or simple trachelectomy. Patients with suboptimal response (residual lesion ≥2 cm) will go off-study and receive definitive treatment as per local protocol. The follow-up is three years. The primary outcome is the rate of functional uterus defined as successful FSS and no adjuvant therapy. Secondary outcomes include the safety of NACT and FSS, the response rate to NACT, and the recurrence-free and overall